MX9800922A - Quinolonas y su uso terapeutico. - Google Patents

Quinolonas y su uso terapeutico.

Info

Publication number
MX9800922A
MX9800922A MX9800922A MX9800922A MX9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A MX 9800922 A MX9800922 A MX 9800922A
Authority
MX
Mexico
Prior art keywords
quinolones
therapeutic use
quinolone
carboxamides
phosphodiesterase
Prior art date
Application number
MX9800922A
Other languages
English (en)
Inventor
Steven Colin Beasley
John Gary Montana
Hazel Joan Dyke
Alan Findlay Haughan
Karen Ann Runcie
David Thomas Manallack
George Martin Buckley
Robert James Maxey
Hannah Jayne Kendall
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515811.9A external-priority patent/GB9515811D0/en
Priority claimed from GBGB9526377.8A external-priority patent/GB9526377D0/en
Priority claimed from GBGB9605868.0A external-priority patent/GB9605868D0/en
Priority claimed from GBGB9611898.9A external-priority patent/GB9611898D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of MX9800922A publication Critical patent/MX9800922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

1-alquil-substituido-quinolona-3-carboxamidas tienen utilidad terapéutica vía inhibicion de la actividad de la Fosfodiesterasa IV esterasa y/o del Factor de necrosis Tumoral.
MX9800922A 1995-08-02 1996-08-02 Quinolonas y su uso terapeutico. MX9800922A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9515811.9A GB9515811D0 (en) 1995-08-02 1995-08-02 Novel compounds
GBGB9526377.8A GB9526377D0 (en) 1995-12-22 1995-12-22 Novel compounds
GBGB9605868.0A GB9605868D0 (en) 1996-03-20 1996-03-20 Novel compounds
GBGB9611898.9A GB9611898D0 (en) 1996-06-07 1996-06-07 Quinolones and their therapeutic use
PCT/GB1996/001862 WO1997004779A1 (en) 1995-08-02 1996-08-02 Quinolones and their therapeutic use

Publications (1)

Publication Number Publication Date
MX9800922A true MX9800922A (es) 1998-05-31

Family

ID=27451319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800922A MX9800922A (es) 1995-08-02 1996-08-02 Quinolonas y su uso terapeutico.

Country Status (12)

Country Link
US (1) US5891878A (es)
EP (1) EP0841929B1 (es)
JP (1) JPH11513021A (es)
AT (1) ATE239477T1 (es)
AU (1) AU696390B2 (es)
CA (1) CA2225552A1 (es)
DE (1) DE69628019T2 (es)
DK (1) DK0841929T3 (es)
ES (1) ES2193252T3 (es)
MX (1) MX9800922A (es)
PT (1) PT841929E (es)
WO (1) WO1997004779A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
ES2248923T3 (es) * 1997-12-22 2006-03-16 PHARMACIA & UPJOHN COMPANY LLC 4-hydroxiquinolin-3-carboxamidas y hidrazidas como agentes antivirales.
IT1302677B1 (it) * 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
WO2001081318A1 (en) 2000-03-21 2001-11-01 Pharmacia & Upjohn Company 4-hydroxycinnoline-3-carboxyamides as antiviral agents
JP2003528087A (ja) 2000-03-21 2003-09-24 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−オキソ−１，４−ジヒドロ−３−シンノリンカルボキサミド
NZ521523A (en) 2000-03-21 2004-05-28 Upjohn Co 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents
MXPA02009249A (es) 2000-03-21 2003-03-12 Upjohn Co 4-oxo-1,4-dihidro(1,8)naftiridin-3-carboxamidas como agentes antivirales.
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
CA2433467A1 (en) 2001-03-01 2002-09-12 Joseph W. Strohbach Substituted quinolinecarboxamides as antiviral agents
JP2005504808A (ja) * 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
US7186707B2 (en) * 2002-04-01 2007-03-06 University Of Florida Prodrugs for use as ophthalmic agents
US20070213310A1 (en) * 2002-04-01 2007-09-13 Laszlo Prokai Prodrugs for Use as Ophthalmic Agents
US7300926B2 (en) * 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
ES2279946T3 (es) * 2002-04-01 2007-09-01 University Of Florida Research Foundation, Inc. Quinoles esteroideos como profarmacos de antioxidantes.
WO2004069248A1 (en) * 2002-12-09 2004-08-19 University Of Florida Prodrugs for use a ophthalmic agents
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
DE102004004971B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
RU2528046C2 (ru) * 2004-06-24 2014-09-10 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
EP2502913A3 (en) * 2004-06-24 2013-11-27 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2489659B1 (en) * 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
DE102004035203A1 (de) 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituierte Chinolone
DE102005030524A1 (de) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituierte Chinolone II
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
WO2007075946A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
ES2790700T3 (es) 2005-12-28 2020-10-28 Vertex Pharma Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida
DE102006005861A1 (de) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituierte Chinolone III
ES2427247T3 (es) * 2006-03-13 2013-10-30 Kyorin Pharmaceutical Co., Ltd. Aminoquinolonas como inhibidores de GSK-3
BRPI0919930A2 (pt) 2008-10-23 2016-02-16 Vertex Pharma moduladores de regulador de condutância transmembrana de fibrose cística
BRPI1011506B8 (pt) 2009-03-20 2021-05-25 Vertex Pharma processo para a fabricação de moduladores de regulador de condutância de transmembrana de fibrose cística
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CN104470518A (zh) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 药物组合物及其施用
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
WO2016057730A1 (en) 2014-10-07 2016-04-14 Strohmeier Mark Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CN107998131B (zh) * 2017-12-27 2019-09-24 湖北工业大学 芳香酯类化合物用于制备抗adv-7病毒药物
CN111646941A (zh) * 2020-07-17 2020-09-11 天津科技大学 一种磺酰胺类衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524558A (en) * 1967-03-30 1970-08-18 American Mach & Foundry Cargo loading means and method
US3524858A (en) * 1967-05-18 1970-08-18 Warner Lambert Pharmaceutical 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
FR2564832B1 (fr) * 1984-05-23 1987-05-15 Panmedica Sa Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant
US4786644A (en) * 1987-11-27 1988-11-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinolinecarboxamide
JPH02124871A (ja) * 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体

Also Published As

Publication number Publication date
DE69628019D1 (de) 2003-06-12
AU696390B2 (en) 1998-09-10
EP0841929A1 (en) 1998-05-20
CA2225552A1 (en) 1997-02-13
PT841929E (pt) 2003-09-30
ATE239477T1 (de) 2003-05-15
AU6626396A (en) 1997-02-26
DK0841929T3 (da) 2003-09-01
WO1997004779A1 (en) 1997-02-13
ES2193252T3 (es) 2003-11-01
EP0841929B1 (en) 2003-05-07
JPH11513021A (ja) 1999-11-09
US5891878A (en) 1999-04-06
DE69628019T2 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
MX9800921A (es) Quinolonas y su uso terapeutico.
MX9800922A (es) Quinolonas y su uso terapeutico.
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
IL136738A0 (en) Inhibition of p38 kinase activity using substituted heterocyclic ureas
HK1031832A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
CA2290520A1 (en) Inhibition of p38 kinase activity by aryl ureas
AU3738393A (en) Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
DK0696205T3 (da) Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
AU6097094A (en) Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
AU5093593A (en) Inhibition of tumor metastasis via neutralization of tissue factor function
AU5788396A (en) Methods of inhibition or killing of cancer cells
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
AU3000297A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
AU5354394A (en) Beta -agonist, alpha1-agonist, and/or alpha2-antagonist treatment of neurodegenerative diseases and central nervous system trauma
AU5962396A (en) Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and deri vatives thereof
AU7012496A (en) Compounds and methods for treatment and diagnosis of prostate cancer
AU3400297A (en) Gm-csf administration for the treatment and prevention of recurrence of brain tumors
AU7278294A (en) Use of quinoline-3-carboxamide compounds for inhibiting the production of tumour necrosis factor (tnf) and/or for the treatment of septic shock
AU4808593A (en) Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
AU6381996A (en) Inhibition of cancer cell growth, proliferation and metastas is using n,n'-dibenzyl-alpha,omega-diaminoalkanes
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
HK1063004A1 (en) Oxalatoplatin and 5-fluorouracil for combination therapy of cancer
EP0656069A4 (en) CELL PROLIFERATION INHIBITORS, THEIR PRODUCTION AND USE.
AU2265695A (en) The use of sertraline to treat cancer patients

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees